Literature DB >> 22681969

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.

M M Santoro1, D Armenia, L Fabeni, M Santoro, C Gori, F Forbici, V Svicher, A Bertoli, L Dori, M Surdo, E Balestra, G Palamara, E Girardi, G Angarano, M Andreoni, P Narciso, A Antinori, F Ceccherini-Silberstein, C F Perno.   

Abstract

Through this study we evaluated whether the HIV-1 tropism determined by genotypic analysis correlates with HIV-1 markers, such as CD4 cell count and plasma HIV-RNA. The analysis was performed on 1221 HIV-1 B-subtype infected patients with an available V3 sequence (all maraviroc naive). Of them, 532 were antiretroviral therapy (ART) naive and 689 ART experienced. Tropism determination was performed by using the geno2pheno (co-receptor) algorithm set at a false-positive rate (FPR) of 10% and 2%. Potential associations of FPR with CD4 cell count and viraemia were evaluated. Association of V3 mutations with genotypic-determined tropism was also evaluated according to different FPR ranges. About 26% of patients (either ART naive or ART experienced) were infected by X4-tropic viruses (using the classical 10% FPR cut-off). However, a significantly lower proportion of ART-naive patients had FPR ≤ 2% in comparison with ART-experienced patients (4.9% vs. 12.6%, respectively, p <0.001). The risk of advanced HIV-1 infection (with CD4 cell count ≤ 200 cells/mm(3)) was significantly greater in X4-infected patients, either ART-naive (OR (95% CI)), 4.2 (1.8-9.2); p 0.0006) or ART-experienced (2.3 (1.4-3.6); p 0.0003), with FPR set at 2% (but not at 10%). This finding was confirmed by multivariable logistic analysis. No relationship was found between viraemia and FPR ≤2%. Some X4-related mutations were significantly associated with FPR ≤2% (ART-naive patients, S11R, Y21V, G24K and G24R, p ≤0.001; ART-experienced patients, Y7K, S11R, H13Y, p ≤0.002). In conclusion, these findings show that within the context of genotypically-assessed CXCR4 tropism, FPR ≤2% defines (far better than 10%-FPR) a viral population associated with low CD4 rank, with potentially greater cytopathic effect, and with more advanced disease.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22681969     DOI: 10.1111/j.1469-0691.2012.03905.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  7 in total

1.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

2.  A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART.

Authors:  Daniele Armenia; Cathia Soulie; Domenico Di Carlo; Lavinia Fabeni; Caterina Gori; Federica Forbici; Valentina Svicher; Ada Bertoli; Loredana Sarmati; Massimo Giuliani; Alessandra Latini; Evangelo Boumis; Mauro Zaccarelli; Rita Bellagamba; Massimo Andreoni; Anne-Geneviève Marcelin; Vincent Calvez; Andrea Antinori; Francesca Ceccherini-Silberstein; Carlo-Federico Perno; Maria Mercedes Santoro
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

3.  Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses-an analysis of a prospective country-wide cohort.

Authors:  Amare Worku Kalu; Nigus Fikrie Telele; Solomon Gebreselasie; Daniel Fekade; Samir Abdurahman; Gaetano Marrone; Anders Sönnerborg
Journal:  BMC Infect Dis       Date:  2017-01-06       Impact factor: 3.090

4.  Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.

Authors:  Matteo Surdo; Emanuela Balestra; Patrizia Saccomandi; Fabiola Di Santo; Marco Montano; Domenico Di Carlo; Loredana Sarmati; Stefano Aquaro; Massimo Andreoni; Valentina Svicher; Carlo Federico Perno; Francesca Ceccherini-Silberstein
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

5.  Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group.

Authors:  V Svicher; C Alteri; M Montano; A Nori; R D'Arrigo; M Andreoni; G Angarano; A Antinori; G Antonelli; T Allice; P Bagnarelli; F Baldanti; A Bertoli; M Borderi; E Boeri; I Bon; B Bruzzone; R Barresi; S Calderisi; A P Callegaro; M R Capobianchi; F Gargiulo; F Castelli; R Cauda; F Ceccherini-Silberstein; M Clementi; A Chirianni; M Colafigli; A D'Arminio Monforte; A De Luca; A Di Biagio; G Di Nicuolo; G Di Perri; F Di Santo; G Fadda; M Galli; W Gennari; V Ghisetti; A Costantini; A Gori; R Gulminetti; F Leoncini; G Maffongelli; F Maggiolo; R Maserati; F Mazzotta; G Meini; V Micheli; L Monno; C Mussini; S Nozza; S Paolucci; G Palù; S Parisi; G Parruti; A R Pignataro; T Quirino; M C Re; G Rizzardini; M Sanguinetti; R Santangelo; R Scaggiante; G Sterrantino; O Turriziani; M L Vatteroni; C Viscoli; V Vullo; M Zazzi; A Lazzarin; C F Perno
Journal:  Infection       Date:  2013-10-22       Impact factor: 3.553

6.  HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension.

Authors:  Brandy E Wade; Kristi M Porter; Sharilyn Almodovar; Justin M Smith; Robert A Lopez-Astacio; Kaiser Bijli; Bum-Yong Kang; Sushma K Cribbs; David M Guidot; Deborah Molehin; Bryan K McNair; Laura Pumarejo-Gomez; Jaritza Perez Hernandez; Ethan A Salazar; Edgar G Martinez; Laurence Huang; Cari F Kessing; Edu B Suarez-Martinez; Kevin Pruitt; Priscilla Y Hsue; William R Tyor; Sonia C Flores; Roy L Sutliff
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

7.  Association of X4 tropism with disease progression in antiretroviral-treated children and adolescents living with HIV/AIDS in São Paulo, Brazil.

Authors:  Flávia Jacqueline Almeida; Mayra Simioni Zaparoli; Denise Helena Moreira; Jaqueline de Souza Cavalcanti; Rosangela Rodrigues; Eitan Naaman Berezin; João Leandro de Paula Ferreira; Marco Aurélio Palazzi Sáfadi; Luis Fernando de Macedo Brígido
Journal:  Braz J Infect Dis       Date:  2013-11-22       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.